Actionable news
All posts from Actionable news
Actionable news in PFE: PFIZER Inc,

Gemphire Therapeutics' Oral Cholesterol Drug Could Have $2.8 Billion Potential In U.S. Market

GEMP, Pfizer, Inc. NYSE:PFE - Gemphire Therapeutics' Oral Cholesterol Drug Could Have $2.8 Billion Potential In U.S. Market

Canaccord Genuity said Gemphire Therapeutics Inc GEMP's oral cholesterol drug Gemcabene has a peak U.S. market potential of $2.8 billion. The firm initiated coverage of the stock with a Buy rating.

The brokerage also set a price target of $17, implying a potential upside of 67 percent over Monday's close. On Tuesday, shares gaped open higher at $10.49 and have touched a new 52-week high of $11.33.

"Importantly, we feel gemcabene's oral formulation should enable pricing far below highly efficacious but expensive PCSK9 drugs, enabling meaningful uptake. Assuming positive data, we believe the drug could reach the US market in the broader cholesterol populations by 2020," analyst John Newman wrote in a note.

Related Link: Argus Upgrades AstraZeneca To Buy, Says Discount Is Too Steep Against Pipeline Potential

Gemcabene, which was licensed from Pfizer Inc. PFE, has shown no evidence of drug-drug interactions with statins at any statin dose level, which bodes well for the safety profile of the drug.

"Combination therapy with statins is critical since statins are the preferred therapy for high cholesterol and are generic. We believe that the ability to safely combine gemcabene with statins is also very important to FDA from a safety perspective, which we view as an advantage for the company," Newman added.

At time of writing, shares of Gemphire had climbed 11.45 percent on the day to $11.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Aug 2016JefferiesInitiates Coverage onBuy
Aug 2016RBC CapitalInitiates Coverage onOutperform
Aug 2016Canaccord GenuityInitiates Coverage onBuy

© 2016 Benzinga does not provide investment advice. All rights reserved.